643(top 1%)
papers
25.2K(top 1%)
citations
77(top 1%)
h-index
145(top 1%)
g-index
792
all documents
29.4K
doc citations
3.7K
citing journals

Top Articles

#TitleJournalYearCitations
1Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manualCa-A Cancer Journal for Clinicians20171,748
2Whole-genome landscapes of major melanoma subtypesNature20171,120
3PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaNew England Journal of Medicine20181,072
4Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Lancet, The20171,066
5[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialLancet, The2021629
6Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyCancer Cell2019620
7Polychemotherapy in advanced non small cell lung cancer: a meta-analysisLancet, The1993494
8A derived neutrophil to lymphocyte ratio predicts survival in patients with cancerBritish Journal of Cancer2012399
9Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trialLancet Oncology, The2015339
10Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trialLancet Oncology, The2020334
11Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab TherapyJAMA Oncology2019307
12High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic TherapyClinical Cancer Research2010285
13Cancer Patient Disclosure and Patient-Doctor Communication of Complementary and Alternative Medicine Use: A Systematic ReviewOncologist2012273
14Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 studyLancet Oncology, The2010268
1568Ga‐PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatmentBJU International2016242
16Fertility- and Menopause-Related Information Needs of Younger Women With a Diagnosis of Early Breast CancerJournal of Clinical Oncology2005235
17Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 AntibodiesJAMA Oncology2018235
18Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trialLancet Oncology, The2020230
19miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical CancerClinical Cancer Research2009229
20Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic SignificanceTheranostics2017215
21A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastomaNeuro-Oncology2016212
22Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in MelanomaClinical Cancer Research2017206
23Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibJournal of Clinical Oncology2018204
24Molecular Heterogeneity in Glioblastoma: Potential Clinical ImplicationsFrontiers in Oncology2015198
25A group cognitive behaviour therapy programme with metastatic breast cancer patientsPsycho-Oncology1999194
26Survivorship care plans in cancer: a systematic review of care plan outcomesBritish Journal of Cancer2014188
27Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trialSupportive Care in Cancer2012182
28Clinical Development of TargomiRs, a miRNA Mimic-Based Treatment for Patients with Recurrent Thoracic CancerEpigenomics2016182
29Impact of Medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trialAnnals of Oncology2010179
30The contribution of cytotoxic chemotherapy to 5-year survival in adult malignanciesClinical Oncology2004175
31Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanomaAnnals of Oncology2019174
32Fatal pulmonary toxicity resulting from treatment with gemcitabineCancer1997173
33Further insights into the natural history and management of primary cutaneous neuroendocrine (Merkel cell) carcinomaInternational Journal of Radiation Oncology Biology Physics1995169
34Bisphosphonates and other bone agents for breast cancerThe Cochrane Library2018169
35Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumLancet Oncology, The2019165
36A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancerBritish Journal of Cancer1990163
37Effects of group CBT on the survival time of patients with metastatic breast cancerPsycho-Oncology1999155
38Anatomic Boundaries of the Clinical Target Volume (Prostate Bed) After Radical ProstatectomyInternational Journal of Radiation Oncology Biology Physics2007150
39Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan ChemotherapyJournal of Clinical Oncology2009146
40Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancerAnnals of Oncology2018146
41Patterns of alternative medicine use by cancer patientsMedical Journal of Australia1996144
42Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinomaAnnals of Oncology2014139
43Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of ProgressionClinical Genitourinary Cancer2019137
44FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanomaAnnals of Oncology2018132
45Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancerBritish Journal of Cancer2014129
46Radioembolization versus Standard Care of Hepatic Metastases: Comparative Retrospective Cohort Study of Survival Outcomes and Adverse Events in Salvage PatientsJournal of Vascular and Interventional Radiology2012122
47Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing2020122
48Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trialLancet, The2001120
49Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT studyBritish Journal of Dermatology2020119
50Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyCancer Chemotherapy and Pharmacology2017114